TruClance is manufactured by Synergy Pharmaceuticals Inc. [1] Synergy Pharmaceuticals Inc. is a biopharmaceutical company that develops and commercializes novel gastrointestinal and oncology therapeutics. [1]
What is TruClance used for?
TruClance is a guanylate cyclase-C (GC-C) agonist that treats adults with chronic idiopathic constipation (CIC) and irritable bowel syndrome with diarrhea (IBS-D). [2]
How does TruClance work?
TruClance works by activating the guanylate cyclase-C receptor in the intestinal epithelium. This activation leads to an increase in cyclic guanosine monophosphate (cGMP), which stimulates fluid secretion into the intestinal lumen and accelerates intestinal transit. [2]
When did TruClance get approved?
The U.S. Food and Drug Administration (FDA) approved TruClance for the treatment of CIC in adults in August 2017. [3] Approval for IBS-D in adults followed in November 2017. [3]
What are the side effects of TruClance?
Common side effects of TruClance include diarrhea, nausea, and abdominal pain. [2]
Who are TruClance's competitors?
Other medications used to treat CIC and IBS-D include linaclotide (Linzess) and lubiprostone (Amitiza). [4]
What is the patent status of TruClance?
Information regarding the specific patents for TruClance and their expiration dates can be found on DrugPatentWatch.com. [5]
Sources
1. Synergy Pharmaceuticals Inc. (n.d.). Our Company. Retrieved from https://www.synergypharma.com/
2. FDA. (2017, August 30). FDA approves Trulance (plecanatide) for the treatment of chronic idiopathic constipation. Retrieved from https://www.fda.gov/
3. FDA. (2017, November 16). FDA approves Trulance (plecanatide) for the treatment of irritable bowel syndrome with diarrhea. Retrieved from https://www.fda.gov/
4. WebMD. (n.d.). Irritable Bowel Syndrome with Diarrhea Treatments. Retrieved from https://www.webmd.com/
5. DrugPatentWatch.com. (n.d.). TruClance Patent Information. Retrieved from https://www.drugpatentwatch.com/